Bioactivity of prolactin in systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 22, Issue 2, 2004, Pages 145-150

  La Montagna, Giovanni ^a   Meli, Rosaria ^b   Criscuolo, Tullio ^a   D'Angelo, Salvatore ^a   Valentini, Gabriele ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Bioactive prolactin; Disease activity; Disease severity; Systemic sclerosis

Indexed keywords

C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYCHLOROQUINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; OMEPRAZOLE; PENICILLAMINE; PREDNISONE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROLACTIN; PROSTACYCLIN DERIVATIVE; RECEPTOR SUBTYPE; VASOACTIVE AGENT; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ARTICLE; CELL ASSAY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; HYPERPROLACTINEMIA; LYMPHOMA CELL LINE; MALE; NONHUMAN; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RADIOIMMUNOASSAY; RAT; RATING SCALE; SERODIAGNOSIS; SKIN MANIFESTATION; SYSTEMIC DISEASE; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CELL DIVISION; CELL LINE, TUMOR; FEMALE; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROLACTIN; RECEPTORS, INTERLEUKIN-2; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SKIN; VON WILLEBRAND FACTOR;

EID: 1842607206     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. LAVALLE C: Prolactin - A hormone with immunoregulatory properties that leads to new therapeutic approaches in rheumatic diseases. J Rheumatol 1992; 19: 839-41.
2. JARA LJ, LAVALLE C, FRAGA A et al.: Prolactin, immunoregulation, and autoimmune diseases. Semin Arthritis Rheum 1991; 20: 273-84.
3. McMURRAY R, KEISLER D, KANUEKEL K, IZUI S, WALZER SE: Prolactin influences autoimmune disease activity in the female B/W mouse. J Immunol 1991; 147: 780-7.
4. PAUZNER R, UROWITZ MB, GLADMAN DD, GOUGH JM: Prolactin in systemic lupus erythematosus. J Rheumatol 1994; 21: 2064-7.
5. STRAUB RH, ZEUNER M, LOCK G, SCHOLMERICH J, LANG B: High prolactin and low dehydroepiandrosterone sulphate serum levels in patients with severe systemic sclerosis. Br J Rheumatol 1997; 36: 426-32.
6. La MONTAGNA G, BARUFFO A, PASQUALI D, BELLASTELLA A, TIRRI G, SINISI AA: Assessment of pituitary gonadotropin release to gonadotropin releasing hormone/thyroid stimulating hormone stimulation in women with systemic sclerosis. Rheumatology 2001; 40: 310-4.
7. SHAHIN AA, ABDOH S, ABDELRAZIK M: Prolactin and thyroid hormones in patients with systemic sclerosis: Correlations with disease manifestations and activity. Z Rheumatol 2002; 61: 703-9.
8. MOSZKORZOVA L, LACINOVA Z, MAREK J, MUSILOVA L, DOHNALOVA A, DOSTAL C: Hyperprolactinaemia in patients with systemic lupus erythematosus. Clin Exp Rheumatol 2002; 20: 807-12.
9. PACILIO M, MIGLIARESI S, MELI R, AMBROSONE L, BIGLIARDO B, Di CARLO R: Elevated bioactive prolactin levels in systemic lupus erythematosus - Association with disease activity. J Rheumatol 2001; 28: 2216-21.
10. LANGER G, SACHAR EJ: Dopaminergic factor in human prolactin regulation: Effect of neuroleptic and dopamine. Psychoneuroendocrinology 1997; 2:373-8.
11. CUTOLO M, PRETE C, WALKER J: Is stress a factor in the pathogenesis of autoimmune rheumatic diseases ? Clin Exp Rheumatol 1999; 17: 515-8.
12. HATTORI N, INAGAKI C: Anti-prolactin autoantibodies cause asymptomatic hyperprolactinemia: Bioassay and clearance studies of PRL-immunoglobulin G complex. J Clin Endocrinol Metab 1997; 82: 3107-10.
13. HILTY C, BRUHLMANN P, SPROTT H et al.: Altered diurnal rhytm of prolactin in systemic sclerosis. J Rheumatol 2000; 27: 2160-5.
14. LEANOS-MIRANDA A, PASCOE-LIRA D, CHAVEZ-RUEDA KA, BLANCO-FAVELA F: Antiprolactin autoantibodies in systemic lupus erythematosus: Frequency and correlation with prolactinemia and disease activity. J Rheumatol 2001; 28: 1546-53.
15. SUBRAMANIAN MG, SPIRTOS NJ, MOGHISSI KS, MAGYAR DM, HAYES MF, GALA RR: Correlation and comparison of Nb2 lymphoma cell bioassay with radioimmunoassay for human prolactin. Fertil Steril 1984; 42: 870-4.
16. ATAYA KM, SUBRAMANIAN MG, LAWSON DM, GALA RR: Euprolactinemic galactorrhea response of bioassayable prolactin to thyrotropin-releasing hormone. J Reproduct Med 1996; 41: 156-60.
17. SCUSSEL-LONZETTI L, JOYAL F, RAYNAULD JP et al.: Predicting mortality in systemic sclerosis. Analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine 2002; 81: 154-67.
18. GIORDANO M, VALENTINI G, MIGLIARESI S, PICILLO U, VATTI M: Different antibody patterns and different prognoses in patients with sclerodermia with various extent of skin sclerosis. J Rheumatol 1986; 13: 911-16.
19. JAMESON JL: The pituitary. In BENNET JC and PLUM F (Eds.): Cecil's Textbook of Medicine. 20th ed. Philadelphia, W.B. Saunders, 1996: 1205-21.
20. TANAKA T, SHIU RPC, GOUT PW, BEER CT, NOBLE RL, FRIESEN HG: A new sensitive and specific bioassay for lactogenic hormones: Measurement of prolactin and grwth hormone in human serum. J Clin Endocrinol Metab 1980; 51: 1058-63.
21. CLEMENTS PJ, LACHENBRUCH, SEIBOLD JR et al.: Inter- and intra-observer variability of total skin tickness score (modified-Rodnan) in systemic sclerosis (SSc). J Rheumatol 1995; 22: 1281-5.
22. MEDSGER TA Jr, SILMAN AJ, STEEN VD et al.: A disease severity scale for systemic sclerosis: Development and testing. J Rheumatol 1999; 26: 2159-67.
23. VALENTINI G, DELLA ROSSA A, BOMBARDIERI S et al.: European multicentre study to define disease activity criteria for systemic sclerosis. II Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60:592-8.
24. BEN-JONATHAN N, MERSHON JL, ALLEN DL, STEINMETZ RW: Extra-pituitary prolactin: Distribution, regulation, function, and clinical aspects. Endocr Rev 1996; 17: 639-69.
25. JARA LJ, GOMEZ-SANCHEZ C, SILVEIRA LH, MARTINEZ-OSUNA P, VASEY FB, ESPINOZA LR: Hyperprolactinemia in systemic lupus erythematosus: Association with disease activity. Am J Med Sci 1992; 303: 222-6.
26. SCALI JJ, BARCENA P, VISENTINI S, SALOMON J, MORALES E: Hyperprolactinemia, uveitis, and systemic lupus erythematosus: clinical-immunological correlation. Ann NY Acad Sci 1999; 8796: 155-8.
27. HATTORI N, ISHIHARA T, IKEKUBO K, MORIDERA K, HINO M, KURAHACHI N: Autoantibody to human prolactin in patients with idiopathic hyperprolactinemia. J Clin Endocrinol Metab 1992; 5: 1226-9.
28. FLETCHER-CHIAPPINI SE, COMPTON MM, LA VOIE HA, DAY EB, WITORSCH RJ, COMPTON MM: Glucocorticoid prolactin interactions in Nb2 lymphoma cells: Antiproliferative versus anticytolitic effects. Proc Soc Exp Biol Med 1993; 202: 345-52.
29. NAGY E, CHALMERS IM, BARAGAR FD, FRIESEN HG, BARCZI I: Prolactin deficiency in rheumatoid arthritis. J Rheumatol 1991; 18: 1662-8.
30. PICILLO U, MIGLIARESI S, VATTI M, MARCIALIS MR, FERRUZZI AM, TIRRI G: Demographic differences in the frequencies of scleroderma-related autoantibodies. Arthritis Rheum 1993; 36: 1332.